First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. - Wikidata - wikimedia - TriplyDB

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

http://www.wikidata.org/entity/Q46871175

about

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues Current management of metastatic brain disease EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.Management of patients with advanced non-small cell lung cancer: role of gefitinib Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.Gefitinib in non small cell lung cancer EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan.Personalized medicine and treatment approaches in non-small-cell lung carcinoma.Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).Epidermal growth factor receptor inhibition and non-small cell lung cancer.Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy Gefitinib for the treatment of non-small-cell lung cancer.Gefitinib in the treatment of advanced non-small-cell lung cancer.Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments.Pharmacotherapy targeting the EGFR oncogene in NSCLC.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis.Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.

P2860

Q21198843-101DCE86-4959-435A-9A17-E670F7229520 Q24625201-9E25BB0C-3FFC-495B-B3C4-7B6EFA7B58D4 Q24653036-93F682AC-A34C-49F4-BE87-701BF9E3049B Q33475484-7E9C35AF-A481-4F54-812E-9ED7DB3D232A Q33574958-FE58A865-F2AE-4DAE-B24E-640288F8C204 Q33892597-62C33DE9-336E-4DFF-8B1D-8D6676F5AF5A Q34159240-6B67364A-9535-488F-AA87-DB41625711C2 Q34571839-95F625F1-361E-47DE-B631-6879B9393094 Q35031807-AC5B6717-9855-4126-9C12-F72A0C77C2C0 Q35164306-30BA4A72-E152-4F9F-BF72-FB05D51A150E Q35628121-1194E971-3FF6-4568-BFA1-CA02312F2370 Q36194473-B999C904-2D44-4E9F-8065-49354E73566F Q36441548-0C9B6B20-9A7D-4576-B9B3-C7EDBCCAA864 Q36494159-77A67B35-9955-4B90-BD29-838B019689EC Q36504349-AC22DEA0-ABEA-4BDB-B705-A0CF1E2644E9 Q36612451-36B34500-DFD3-46EB-935A-CB165C991F5D Q36628704-666F383B-454B-4D57-8B24-5E0D956026D6 Q36905639-1B5D2D86-A843-4362-B7E3-AB530F573C45 Q36966043-16CBFBC2-C9EC-4AD1-975A-259DCEB52A2F Q37102068-B4F863ED-EF44-4467-8AB3-65A92489121D Q37282841-3CC78EBB-327F-42DD-9A1C-0E958FD3BF2F Q37347532-17B6EEB9-2FD7-4A6A-8301-A8EAE7821943 Q37357287-124F2B8E-9999-4AEE-BF34-3E91EFC39309 Q37449013-A1F1D94A-23D4-44C0-8397-082BD3660CBA Q37645161-F4240A57-88B4-4197-AC7B-73473D18AD32 Q37688183-EA6036AB-90D9-46AE-8844-8A5230F79C57 Q37701147-2F95794C-0964-4495-9D53-62D3DD293BB7 Q37724215-E7EF77B9-F82F-4299-B307-55526DA41D25 Q38088215-F58F9DEE-3397-415B-B3D1-B32E5D779BA7 Q38248997-CFA72270-4225-438E-8D3A-83662CD6A8A7 Q38289406-BF9C61DD-F4AD-4F65-B50D-BDEC69EE5046 Q38770028-47497B10-9C5D-428A-9217-23A1BF357156 Q40041019-FA7BF381-FB86-4DEC-AC4F-04CEE08E328A Q40177381-61ADDE4A-71D9-457B-9F35-44749B44A1C4 Q41860438-E45080A6-A0FD-4F33-9C85-93E8A8307227 Q44456952-688E9645-FE86-4601-8EC6-8D85E845B1CA Q48100116-97290EA1-EB0B-4DA8-B109-6BCC6A110A54 Q51011218-76346C99-48B0-4278-8397-E2F47B99ACC0

P2860

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

http://www.wikidata.org/entity/Q46871175

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

First-line single agent treatm ...... lung cancer: a phase II study.

@en

First-line single agent treatm ...... lung cancer: a phase II study.

@nl

type

label

First-line single agent treatm ...... lung cancer: a phase II study.

@en

First-line single agent treatm ...... lung cancer: a phase II study.

@nl

prefLabel

First-line single agent treatm ...... lung cancer: a phase II study.

@en

First-line single agent treatm ...... lung cancer: a phase II study.

@nl

P1433

Q46871175-214F8CA9-4AD7-42AC-9965-AEFA8CAAEA7A

P1476

Q46871175-B703EBE3-30A4-4FC9-B752-AD99D46F4524

P2093

Q46871175-74F0D2CB-0EA5-48D7-906D-B2CFA4519CBA

Q46871175-784B4EF7-E7C1-4E3E-94FC-D4C02BACB8A7

Q46871175-9E8F5295-776F-4548-96A4-D13AECE5E2B3

Q46871175-A4957DD4-4D31-4725-9177-9E0E8BC89EF9

Q46871175-BA8FB210-EFEB-452C-BCF8-4A9507E59F9B

Q46871175-CB04295F-4ECD-43FF-BC3A-683EE9D056D1

Q46871175-CB4C07A8-A93D-4B22-9C81-172A681F997B

Q46871175-FBA946FD-97CE-4AF4-9DAC-A837EDE5872F

P304

Q46871175-8BDB5695-7F20-4DB4-8351-1499AA16E4AC

P31

Q46871175-13D35A7F-CB5E-4B5B-BE56-4E0D3F7E6A39

P356

Q46871175-2290FB4F-2305-409A-833D-7F16FF2F9AB9

P407

Q46871175-981D9226-ACB6-4C36-9FA5-13075B77A2B5

P433

Q46871175-3221EF8C-A95D-4655-AC24-9FA1145C6933

P478

Q46871175-93BD851C-B6D5-4059-A080-654957B65DE5

P577

Q46871175-86F972E8-16A1-40C4-88D3-4CCC8FE413D1

P698

Q46871175-A09AB43F-C469-4E5F-AD1A-0F121E833117

P921

Q46871175-DF7B2A88-EB56-4491-8370-A8A1B4A3F3BE

P356

JCO.2005.02.5825

P1433

Journal of Clinical Oncology

P1476

First-line single agent treatm ...... lung cancer: a phase II study.

@en

P2093

Hironobu Ohmatsu

http://www.w3.org/2001/XMLSchema#string

Kaoru Kubota

http://www.w3.org/2001/XMLSchema#string

Kiyotaka Yoh

http://www.w3.org/2001/XMLSchema#string

Koichi Goto

http://www.w3.org/2001/XMLSchema#string

Nagahiro Saijo

http://www.w3.org/2001/XMLSchema#string

Ryutaro Kakinuma

http://www.w3.org/2001/XMLSchema#string

Seiji Niho

http://www.w3.org/2001/XMLSchema#string

Yutaka Nishiwaki

http://www.w3.org/2001/XMLSchema#string

P304

64-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.5825

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16382114

http://www.w3.org/2001/XMLSchema#string

P921